Partager :

Nouvelle offre de technologie : CINFLAM

Postée le 28 juin 2016

New CB2 agonists for the Inflammatory Bowel Diseases treatment—Development of an active drug-candidate per os  



CB2 receptor is highly expressed in immune system and intestinal epithelium cells.

This receptor plays an important role in inflammation.

Studies have shown that a particular selective CB2 receptor agonist reduces colon inflammation in models of colitis induced by mustard oil or by dextran sulfate sodium (DSS).

Many pharmaceutical companies consider the CB2 receptor as a therapeutic target of interest for the treatment of chronic inflammatory diseases or neurodegenerative diseases.

More information  Publiée dans Technologies / ProjetsLA SATT NORD RECRUTE >><< PIA 3 : préparer la France aux défis de demain